MENU
ARKG
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

ARKG stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
ARKG
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ARKG with price predictions
Aug 07, 2026

ARKG's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ARKG turned positive on August 05, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on ARKG as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARKG moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARKG broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ARKG entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Market Cap

The average market capitalization across the ARK Genomic Revolution ETF ETF is 156.87B. The market cap for tickers in the group ranges from 114.24M to 222.32B. AMGN holds the highest valuation in this group at 222.32B. The lowest valued company is RPTX at 114.24M.

High and low price notable news

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was 25%. For the same ETF, the average monthly price growth was 65%, and the average quarterly price growth was 247%. ARCT experienced the highest price growth at 29%, while PACB experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was -7%. For the same stocks of the ETF, the average monthly volume growth was -17% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 79
Price Growth Rating: 47
SMR Rating: 81
Profit Risk Rating: 87
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
ARKG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
ARK ETF Trust155 West 19th Street, 5th FloorNew York
Phone
212-426-7040
Web
www.ark-funds.com
ARKG's MACD Histogram just turned positive